Share on StockTwits

United Therapeutics (NASDAQ:UTHR) EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock on the open market in a transaction dated Thursday, April 17th. The stock was sold at an average price of $98.37, for a total transaction of $590,220.00. Following the transaction, the executive vice president now directly owns 34,832 shares of the company’s stock, valued at approximately $3,426,424. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

UTHR has been the subject of a number of recent research reports. Analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. Separately, analysts at Zacks downgraded shares of United Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Friday, April 4th. They now have a $98.00 price target on the stock. Finally, analysts at Wedbush raised their price target on shares of United Therapeutics from $114.00 to $119.00 in a research note on Wednesday, April 2nd. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. United Therapeutics presently has an average rating of “Hold” and a consensus target price of $95.50.

Shares of United Therapeutics (NASDAQ:UTHR) traded down 2.06% during mid-day trading on Friday, hitting $96.20. 815,235 shares of the company’s stock traded hands. United Therapeutics has a 1-year low of $59.05 and a 1-year high of $116.65. The stock’s 50-day moving average is $96.52 and its 200-day moving average is $95.88. The company has a market cap of $4.856 billion and a P/E ratio of 29.95.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, February 25th. The company reported $2.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $1.37. The company had revenue of $289.02 million for the quarter, compared to the consensus estimate of $295.43 million. Analysts expect that United Therapeutics will post $6.93 EPS for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.